A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Background: Multiple sclerosis is a chronic inflammatory ... [20] In these patients, cognitive function improved and the brain atrophy rate was significantly slowed. Here, immunomodulatory effects ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s ...

Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated ... dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular ...

UK researchers have unveiled an innovative artificial intelligence (AI) tool, named MindGlide, designed to interpret and ...

Roche is investigating more than a dozen medicines for neurological disorders, including Alzheimer's disease, multiple ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H ...

Background:Studies have suggested that T2 lesion activity is prominent in early relapsing-remitting multiple sclerosis, whereas brain atrophy, while seen early, appears more evident in later ...